Carroll Financial Associates Inc. boosted its position in PRA Health Sciences Inc (NASDAQ:PRAH) by 7.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,517 shares of the medical research company’s stock after purchasing an additional 107 shares during the quarter. Carroll Financial Associates Inc.’s holdings in PRA Health Sciences were worth $167,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of PRAH. Enlightenment Research LLC bought a new position in shares of PRA Health Sciences during the fourth quarter valued at $101,000. Quantamental Technologies LLC bought a new position in shares of PRA Health Sciences during the fourth quarter valued at $221,000. Marshall Wace North America L.P. bought a new position in shares of PRA Health Sciences during the third quarter valued at $236,000. D.A. Davidson & CO. increased its holdings in shares of PRA Health Sciences by 5.7% during the fourth quarter. D.A. Davidson & CO. now owns 2,698 shares of the medical research company’s stock valued at $248,000 after acquiring an additional 146 shares in the last quarter. Finally, Stifel Financial Corp increased its holdings in shares of PRA Health Sciences by 40.8% during the fourth quarter. Stifel Financial Corp now owns 2,783 shares of the medical research company’s stock valued at $258,000 after acquiring an additional 807 shares in the last quarter. Institutional investors and hedge funds own 98.14% of the company’s stock.
PRAH has been the subject of several analyst reports. Wolfe Research initiated coverage on PRA Health Sciences in a report on Tuesday, April 2nd. They set a “market perform” rating for the company. BidaskClub downgraded PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, April 10th. ValuEngine upgraded PRA Health Sciences from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Zacks Investment Research downgraded PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, SunTrust Banks raised their price target on PRA Health Sciences to $120.00 and gave the company an “average” rating in a report on Monday, March 4th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company’s stock. PRA Health Sciences currently has an average rating of “Hold” and a consensus price target of $113.22.
TRADEMARK VIOLATION NOTICE: “Carroll Financial Associates Inc. Boosts Holdings in PRA Health Sciences Inc (PRAH)” was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/22/carroll-financial-associates-inc-boosts-holdings-in-pra-health-sciences-inc-prah.html.
About PRA Health Sciences
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.